A Phase 1 Maximum Tolerated Dose Study of SN514-066b in Adult Patients With Deep Partial Thickness Dermal Burns
Latest Information Update: 21 May 2025
At a glance
- Drugs SN 514 (Primary)
- Indications Burns
- Focus Adverse reactions
- Sponsors SERDA Therapeutics
Most Recent Events
- 11 Apr 2025 Planned primary completion date changed from 1 Mar 2026 to 1 May 2026.
- 11 Apr 2025 Planned initiation date changed from 1 Mar 2025 to 31 May 2025.
- 07 Feb 2025 Planned End Date changed from 1 Dec 2025 to 1 May 2026.